Inventor · disambiguated record
Sherry Lynn La Porte
Also filed as: LA PORTE SHERRY · LA PORTE SHERRY L · LA PORTE SHERRY LYNN
15 granted patents·8 pending applications·89 citations·filing 2013–2025
91Inventor score
Top patents by PatentIndex Score
23 records- 0198US9309510B2Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Apr 12, 2016·26 cites·37 claims
- 0296US11859010B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Jan 2, 2024·5 cites·13 claims
- 0396US11236155B2Antibodies to pyroglutamate amyloid-β and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Feb 1, 2022·4 cites·23 claims
- 0496US10669337B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 2, 2020·31 cites·16 claims
- 0594US12460017B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Nov 4, 2025·1 cites·12 claims
- 0692US11472889B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Oct 18, 2022·7 cites·18 claims
- 0791US12084501B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2022·Granted Sep 10, 2024·2 cites·44 claims
- 0890US11161906B2Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2014·Granted Nov 2, 2021·12 cites·45 claims
- 0989US2025034755A1Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1082US11802158B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2020·Granted Oct 31, 2023·1 cites·21 claims
- 1180US2025320286A1Antibodies to pyroglutamate amyloid-b and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2025·Application pending·0 cites
- 1279US12139816B2Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Nov 12, 2024·0 cites·9 claims
- 1377US2024084010A1Bispecific anti-cd3 antibodies, bispecific activatable anti-cd3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1475US2025145711A1Proteins comprising cd3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1574US11198864B2Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2020·Granted Dec 14, 2021·0 cites·34 claims
- 1671US2022106387A1Antibodies to pyroglutamate amyloid-b and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 1766US10947531B2Protease-resistant systems for polypeptide display and methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Mar 16, 2021·0 cites·20 claims
- 1861US12077585B2Proteins comprising kallikrein related peptidase 2 antigen binding domains and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Sep 3, 2024·0 cites·96 claims
- 1961US2021238291A1Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2059US12460001B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2021·Granted Nov 4, 2025·0 cites·50 claims
- 2158US2024409634A1CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCERJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2250US2023151083A1Anti-phf-tau antibodies and uses thereofJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2348US12071466B2Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereofJANSSEN BIOTECH INC·Filed 2020·Granted Aug 27, 2024·0 cites·35 claims
Join the waitlist — get patent alerts
Get an alert when Sherry Lynn La Porte files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →